1718-1719 / 1778
Figure 3: Cancer specific overall survival.
Cancer specific overall survival at 5 years: 74%
CEOS
p
Stage
Ib2-IIB
83%
0,001
III-Iva
41%
Histology
squamous
78%
ns
adenocarcinoma
59,7%
Lymph node
involvement
N0
85
0,01
Npelvic-paraortic+ 72
Npelvic+paraortic+ 35
ERT
3D
66.5% ns
IMRT
75,3%
CTV-HR dose <85 Gy
77%
ns
>85 Gy
82,5&
CTV-HR
volumen
< 30 cc
81,8% ns
>30 cc
67%